RNTX Rein Therapeutics Inc.
Price (delayed)
$1.91
Market cap
$42.01M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.51
Enterprise value
$29.14M
Highlights
The debt has dropped by 100% year-on-year
Rein Therapeutics's net income has plunged by 115% from the previous quarter
Rein Therapeutics's equity has decreased by 45% YoY and by 43% QoQ
Key stats
What are the main financial stats of RNTX
Market
Valuations
Earnings
Shares outstanding
21.99M
Market cap
$42.01M
Enterprise value
$29.14M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.76
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$65.11M
Net income
-$62.88M
EBIT
-$64.43M
EBITDA
-$64.36M
Free cash flow
-$22.29M
Per share
Balance sheet
Liquidity
EPS
-$3.51
EPS diluted
-$3.51
Free cash flow per share
-$1.24
Book value per share
$2.51
Revenue per share
$0
TBVPS
$0.76
Total assets
$62.19M
Total liabilities
$7.8M
Debt
$0
Equity
$54.39M
Working capital
$7.91M
Debt to equity
0
Current ratio
2.38
Quick ratio
2.24
Net debt/EBITDA
0.2
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-67.1%
Return on equity
-73.6%
Return on invested capital
N/A
Return on capital employed
-114.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RNTX stock price
How has the Rein Therapeutics stock price performed over time
Intraday
4.37%
1 week
12.35%
1 month
14.37%
1 year
-61.8%
YTD
-16.96%
QTD
7.91%
Financial performance
How have Rein Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$65.11M
Net income
-$62.88M
Gross margin
N/A
Net margin
N/A
The operating income has dropped by 120% since the previous quarter
Rein Therapeutics's net income has plunged by 115% from the previous quarter
Growth
What is Rein Therapeutics's growth rate over time
Valuation
What is Rein Therapeutics stock price valuation
P/E
N/A
P/B
0.76
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is down by 11% since the previous quarter and by 2.6% year-on-year
Rein Therapeutics's equity has decreased by 45% YoY and by 43% QoQ
RNTX's P/B is 42% below its 5-year quarterly average of 1.3 but 9% above its last 4 quarters average of 0.7
Efficiency
How efficient is Rein Therapeutics business performance
The ROE has plunged by 143% from the previous quarter and by 60% YoY
The ROA has plunged by 141% from the previous quarter and by 60% YoY
Dividends
What is RNTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RNTX.
Financial health
How did Rein Therapeutics financials performed over time
RNTX's quick ratio is down by 43% YoY and by 28% QoQ
RNTX's current ratio is down by 43% year-on-year and by 28% since the previous quarter
The debt is 100% smaller than the equity
The debt has dropped by 100% year-on-year
Rein Therapeutics's equity has decreased by 45% YoY and by 43% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.